CD34(+) Therapy-Related Acute Promyelocytic Leukemia in a Patient Previously Treated for Breast Cancer

Authors

John Savooji, New York Medical College
Fouzia Shakil, New York Medical CollegeFollow
Humayun Islam, New York Medical CollegeFollow
Delong Liu, New York Medical CollegeFollow
Karen Seiter, New York Medical CollegeFollow

First Page

7

Last Page

7

Document Type

Article

Publication Date

3-11-2016

Department

Pathology, Microbiology and Immunology

Second Department

Medicine

Abstract

Therapy-related acute myeloid leukemia (AML) is a long term complication of chemotherapy for a variety of cancers. In most cases, the marrow demonstrates high risk cytogenetics and the prognosis is poor. In a minority of patients "good risk" cytogenetics, including t(15;17)(q22;q12), are seen and the patient's prognosis is similar to those who have de novo disease. Currently we present a patient who developed therapy-related acute promyelocytic leukemia (APL) after chemoradiotherapy for breast cancer. This case was especially atypical because the leukemic cells were CD34(+), which is an unusual immunophenotype for APL. Recognition that this patient had APL, rather than the more common therapy-related MDS or AML, was imperative to initiate chemotherapy in a timely manner.

Recommended Citation

Savooji, J., Shakil, F., Islam, H., Liu, D., & Seiter, K. (2016). CD34(+) therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer. Stem Cell Investigation, 3, 7. doi:10.21037/sci.2016.03.03

Publisher's Statement

Originally published in Stem Cell Investigation. Licensed under CC-BY 4.0. https://doi.org/10.21037/sci.2016.03.03